Elio Adib

2.5k total citations · 1 hit paper
41 papers, 924 citations indexed

About

Elio Adib is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Elio Adib has authored 41 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 16 papers in Surgery and 16 papers in Oncology. Recurrent topics in Elio Adib's work include Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Genomics and Diagnostics (8 papers). Elio Adib is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Genomics and Diagnostics (8 papers). Elio Adib collaborates with scholars based in United States, Netherlands and Norway. Elio Adib's co-authors include Basil S. Karam, Elie A. Akl, Joseph Abi Jaoude, Khalil Baddour, Cindy Traboulsi, Ramez Kouzy, Jabra Zarka, Molly B. El Alam, Afif Kraitem and Amin H. Nassar and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Elio Adib

35 papers receiving 889 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter

2020 586 citations Ramez Kouzy, Joseph Abi Jaoude et al. Cureus profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elio Adib United States	10	459	174	156	153	141	41	924
Joseph Abi Jaoude United States	12	461 1.0×	201 1.2×	148 0.9×	156 1.0×	141 1.0×	65	1.0k
Ramez Kouzy United States	10	460 1.0×	178 1.0×	82 0.5×	156 1.0×	141 1.0×	51	839
Adrian Bailey Canada	13	299 0.7×	192 1.1×	55 0.4×	69 0.5×	78 0.6×	40	880
Dinorah Martinez Tyson United States	18	263 0.6×	156 0.9×	387 2.5×	38 0.2×	45 0.3×	57	1.2k
Elena Soto‐Vega Mexico	14	243 0.5×	112 0.6×	109 0.7×	50 0.3×	46 0.3×	43	1.0k
John J. Brooks United States	8	214 0.5×	64 0.4×	76 0.5×	60 0.4×	79 0.6×	15	394
Jabra Zarka United States	6	459 1.0×	174 1.0×	20 0.1×	152 1.0×	141 1.0×	8	682
Kristen Johnson United States	19	144 0.3×	27 0.2×	118 0.8×	107 0.7×	52 0.4×	43	1.2k
Deanna J. Attai United States	22	192 0.4×	476 2.7×	325 2.1×	29 0.2×	64 0.5×	58	1.3k
Stefania Innocenti United Kingdom	13	432 0.9×	798 4.6×	119 0.8×	78 0.5×	31 0.2×	24	1.5k

Countries citing papers authored by Elio Adib

Since Specialization

Citations

This map shows the geographic impact of Elio Adib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elio Adib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elio Adib more than expected).

Fields of papers citing papers by Elio Adib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elio Adib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elio Adib. The network helps show where Elio Adib may publish in the future.

Co-authorship network of co-authors of Elio Adib

This figure shows the co-authorship network connecting the top 25 collaborators of Elio Adib. A scholar is included among the top collaborators of Elio Adib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elio Adib. Elio Adib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adib, Elio, Amin H. Nassar, Harvey J. Mamon, et al.. (2025). Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer.. Journal of Clinical Oncology. 43(4_suppl). 288–288.

Skelton, William Paul, Jonathan Thomas, Rohit Jain, et al.. (2024). Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer. 22(5). 102143–102143.

Nassar, Amin H., Frances A. Shepherd, Steven H. Lin, et al.. (2024). Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8013–8013. 3 indexed citations

Adib, Elio, et al.. (2024). PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases.. Journal of Clinical Oncology. 42(16_suppl). 2034–2034. 1 indexed citations

Kerepesi, Csaba, Biagio Ricciuti, Amin H. Nassar, et al.. (2024). Association of Baseline Tumor-Specific Neoantigens and CD8⁺ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors. JCO Precision Oncology. 8(8). e2300439–e2300439. 5 indexed citations

Fulgenzi, Claudia Angela Maria, Talal El Zarif, Elio Adib, et al.. (2024). Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.. Journal of Clinical Oncology. 42(3_suppl). 442–442. 1 indexed citations

Fujiwara, Yu, Nobuyuki Horita, Elio Adib, et al.. (2023). Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. The Lancet Oncology. 25(1). 62–75. 26 indexed citations

Nuzzo, Pier Vitale, Elio Adib, Catherine Curran, et al.. (2022). Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clinical Genitourinary Cancer. 20(4). 301–306. 17 indexed citations

Shrestha, Shikshya, Elio Adib, Dean J. Aguiar, et al.. (2022). Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death. Journal of Biological Chemistry. 298(11). 102580–102580. 1 indexed citations

10.

Adib, Elio, Amin H. Nassar, Sarah Abou Alaiwi, et al.. (2022). Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine. 14(1). 39–39. 34 indexed citations

11.

Rakaee, Mehrdad, Elio Adib, Biagio Ricciuti, et al.. (2022). Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC.. Journal of Clinical Oncology. 40(16_suppl). 9065–9065. 5 indexed citations

12.

Adib, Elio, Amin H. Nassar, Talal El Zarif, et al.. (2022). Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2622–2622. 3 indexed citations

13.

Adib, Elio, Talal El Zarif, Dory Freeman, et al.. (2022). FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 40(6_suppl). 549–549. 1 indexed citations

14.

Ramamurthy, Chethan, Amin H. Nassar, Sarah Abou Alaiwi, et al.. (2022). Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groups. Urologic Oncology Seminars and Original Investigations. 40(3). 113.e9–113.e15. 1 indexed citations

15.

Yang, Eddy S., Amin H. Nassar, Elio Adib, et al.. (2021). Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics. 20(8). 1454–1461. 6 indexed citations

16.

Adib, Elio, Katarzyna Klonowska, Krinio Giannikou, et al.. (2021). Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research. 27(14). 3845–3853. 37 indexed citations

17.

Curran, Catherine, Elio Adib, Petros Grivas, et al.. (2021). Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical Genitourinary Cancer. 20(1). 11–16. 5 indexed citations

18.

Adib, Elio, Talal El Zarif, Amin H. Nassar, et al.. (2021). CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. British Journal of Cancer. 126(5). 797–803. 18 indexed citations

19.

Alaiwi, Sarah Abou, Amin H. Nassar, Elio Adib, et al.. (2021). Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Reports. 34(13). 108926–108926. 20 indexed citations

20.

Kouzy, Ramez, Joseph Abi Jaoude, Afif Kraitem, et al.. (2020). Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter. Cureus. 12(3). e7255–e7255. 586 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact